Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Symmons

Showing results (41-50 of 63) with videos related to

Pageof 7
Sort By:
Health Technology Assessment (Winchester, England)|September 13, 2005
The British Rheumatoid Outcome Study Group (BROSG) randomised controlled trial to compare the effectiveness and cost-effectiveness of aggressive versus symptomatic therapy in established rheumatoid arthritisD Symmons, K Tricker, C Roberts, et al.
Arthritis and Rheumatism|September 1, 2007
The performance of anti-cyclic citrullinated peptide antibodies in predicting the severity of radiologic damage in inflammatory polyarthritis: results from the Norfolk Arthritis RegisterM Bukhari, W Thomson, H Naseem, et al.
Rheumatology (Oxford, England)|December 22, 2005
Preventing non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: are older strategies more cost-effective in the general population?R A Elliott, L Hooper, K Payne, et al.
BMJ (Clinical Research Ed.)|August 24, 1996
A simple algorithm to predict the development of radiological erosions in patients with early rheumatoid arthritis: prospective cohort studyP Brennan, B Harrison, E Barrett, et al.
Genes and Immunity|October 11, 2003
Macrophage migration inhibitory factor (MIF) gene polymorphism is associated with susceptibility to but not severity of inflammatory polyarthritisA Barton, R Lamb, D Symmons, et al.
Rheumatology (Oxford, England)|June 15, 2007
Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics RegistryA Brennan, N Bansback, R Nixon, et al.
Annals of the Rheumatic Diseases|June 2, 2000
Proposal to establish a register for the long term surveillance of adverse events in patients with rheumatic diseases exposed to biological agents: the EULAR Surveillance Register for Biological CompoundsA Silman, L Klareskog, F Breedveld, et al.
Arthritis and Rheumatism|April 22, 1999
Quantifying the exact role of HLA-DRB1 alleles in susceptibility to inflammatory polyarthritis: results from a large, population-based studyW Thomson, B Harrison, B Ollier, et al.
Rheumatology (Oxford, England)|July 4, 2002
The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new centuryD Symmons, G Turner, R Webb, et al.
Annals of the Rheumatic Diseases|January 30, 1999
Estimating the burden of musculoskeletal disorders in the community: the comparative prevalence of symptoms at different anatomical sites, and the relation to social deprivationM Urwin, D Symmons, T Allison, et al.
Pageof 7

Showing results (41-50 of 63) with videos related to

Sort By:
Pageof 7
Health Technology Assessment (Winchester, England)|September 13, 2005
The British Rheumatoid Outcome Study Group (BROSG) randomised controlled trial to compare the effectiveness and cost-effectiveness of aggressive versus symptomatic therapy in established rheumatoid arthritisD Symmons, K Tricker, C Roberts, et al.
Arthritis and Rheumatism|September 1, 2007
The performance of anti-cyclic citrullinated peptide antibodies in predicting the severity of radiologic damage in inflammatory polyarthritis: results from the Norfolk Arthritis RegisterM Bukhari, W Thomson, H Naseem, et al.
Rheumatology (Oxford, England)|December 22, 2005
Preventing non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: are older strategies more cost-effective in the general population?R A Elliott, L Hooper, K Payne, et al.
BMJ (Clinical Research Ed.)|August 24, 1996
A simple algorithm to predict the development of radiological erosions in patients with early rheumatoid arthritis: prospective cohort studyP Brennan, B Harrison, E Barrett, et al.
Genes and Immunity|October 11, 2003
Macrophage migration inhibitory factor (MIF) gene polymorphism is associated with susceptibility to but not severity of inflammatory polyarthritisA Barton, R Lamb, D Symmons, et al.
Rheumatology (Oxford, England)|June 15, 2007
Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics RegistryA Brennan, N Bansback, R Nixon, et al.
Annals of the Rheumatic Diseases|June 2, 2000
Proposal to establish a register for the long term surveillance of adverse events in patients with rheumatic diseases exposed to biological agents: the EULAR Surveillance Register for Biological CompoundsA Silman, L Klareskog, F Breedveld, et al.
Arthritis and Rheumatism|April 22, 1999
Quantifying the exact role of HLA-DRB1 alleles in susceptibility to inflammatory polyarthritis: results from a large, population-based studyW Thomson, B Harrison, B Ollier, et al.
Rheumatology (Oxford, England)|July 4, 2002
The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new centuryD Symmons, G Turner, R Webb, et al.
Annals of the Rheumatic Diseases|January 30, 1999
Estimating the burden of musculoskeletal disorders in the community: the comparative prevalence of symptoms at different anatomical sites, and the relation to social deprivationM Urwin, D Symmons, T Allison, et al.
Pageof 7